Evidence map›Paper›PMID 40744950›Full record

ArticleScientific reports2025

Retrospective study of onychomycosis patients treated with ciclopirox 8% HPCH and oral antifungals applying artificial intelligence to electronic health records.

Gastón Roustan, José Luis López Estébaranz, Pablo De La Cueva, Savana Research Group, Francesca Pajuelo, María Luisa Tamarit, Aida Valmaseda, Jordi Galván

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gastón RoustanDermatology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain.ORCID http://orcid.org/0000-0003-3632-9636
José Luis López EstébaranzDermatology Department, Hospital Universitario Fundación Alcorcón, Madrid, Spain.ORCID http://orcid.org/0000-0002-8816-1989
Pablo De La CuevaDermatology Department, Hospital Universitario Infanta Leonor, Madrid, Spain.ORCID http://orcid.org/0000-0003-4807-3551
Savana Research Group
Francesca PajueloAlmirall S.A, Medical Affairs Department, Barcelona, Spain.ORCID http://orcid.org/0000-0001-8339-2406
María Luisa TamaritAlmirall S.A., Research and Development Center, Sant Feliu de Llobregat, Barcelona, Spain.
Aida ValmasedaAlmirall S.A, Global Medical Affairs Department, Barcelona, Spain.ORCID http://orcid.org/0000-0001-6739-0996
Jordi GalvánAlmirall S.A, Global Medical Affairs Department, Barcelona, Spain. jordi.galvan@almirall.com.ORCID http://orcid.org/0000-0002-2435-2129

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a multicenter retrospective analysis of 408 patients diagnosed with onychomycosis who attended three tertiary care Spanish hospitals. The study was conducted to assess the clinical characteristics and outcomes of onychomycosis patients undertaken combined treatment with ciclopirox 8% hydroxypropyl chitosan (CPX 8% HPCH) nail lacquer and oral antifungal agents (terbinafine, itraconazole, and fluconazole). Data were extracted and analyzed using the EHRead

Indexed as

Antifungal AgentsArtificial IntelligenceCiclopiroxOnychomycosisAdministration, OralAdultAgedElectronic Health RecordsFemaleFluconazoleHumansMaleMiddle AgedRetrospective StudiesTerbinafineTreatment OutcomeAntifungal AgentsCiclopiroxFluconazoleTerbinafineArtificial intelligenceCiclopirox 8% HPCHFluconazoleItraconazoleMachine learningOnychomycosisReal-world dataTerbinafine

Identifiers

PMID40744950
PMCPMC12313871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.